Yabao Pharma Forms Generics Pact with Sciecure of the US

Yabao Pharmaceutical announced a strategic partnership with Sciecure Pharma of New Jersey to develop hard-to-make, controlled-release generic drugs for the US and China. Yabao will have rights to commercialize Sciecure products in China, and it will also manufacture products at its GMP facilities for sale in the US and China. Sciecure will retain rights to the products in all other markets. More details.... Stock Symbol: (SHA: 600351) Share this with colleagues: // //